
Cytek Biosciences, Inc.
CTKBNASDAQHealthcareMedical - Devices
前收盤價
US$4.81
+US$0.15 · +3.22%
CTKB公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
47
Fair Value
動能
50
Neutral
情緒
62
Bullish
風險韌性
45
Elevated Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- Wenbin Jiang
- 上市以來
- 2021年7月23日
- 僱員
- 682
市場位置
日內區間
目前US$4.81,
52週區間
目前US$4.81,
- 開盤價
- US$4.64
- 前收盤價
- US$4.66
- 成交量
- 82.03萬
- 0.69× 平均值
- 平均成交量
- 119.63萬
- 日均成交量
- 市值
- 6.21億 USD
- 貝塔
- 1.17
- 市場參考 1
- 50天平均值
- US$4.4326
- 高於平均水平+8.51%
- 200天平均值
- US$4.6113
- 高於平均水平+4.31%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 5.78億 USD
- EV/EBITDA
- -33.23×
- 盈餘收益率
- -10.31%
- 自由現金流收益率
- -1.36%
獲利能力和效率
- 股東權益報酬率
- -19.47%
- 資產報酬率
- -14.42%
- 投入資本報酬率
- -10.28%
財務健康
- 流動比率
- 5.04×
- 奧特曼 Z 分數
- 3.53
- 皮奧特羅斯基 F 分數
- 4 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.01億 USD | 2億 USD | 1.93億 USD | 1.64億 USD | 1.28億 USD |
| 銷貨成本 | 9703.3萬 USD | 8934.7萬 USD | 8358.9萬 USD | 6306.2萬 USD | 4880.6萬 USD |
| 毛利 | 1.04億 USD | 1.11億 USD | 1.09億 USD | 1.01億 USD | 7914.4萬 USD |
| 研究與開發 | 3646.8萬 USD | 3940.2萬 USD | 4415.1萬 USD | 3485.8萬 USD | 2444.2萬 USD |
| 銷售、一般及管理費用 | 1.08億 USD | 9222.7萬 USD | 9312萬 USD | 6792萬 USD | 4554.5萬 USD |
| 營業費用 | 1.45億 USD | 1.32億 USD | 1.37億 USD | 1.03億 USD | 6998.7萬 USD |
| 利息收入 | 221.6萬 USD | 1036萬 USD | 641.3萬 USD | 461.9萬 USD | 4.9萬 USD |
| 利息支出 | 47.4萬 USD | — | 207.1萬 USD | 257.3萬 USD | 174.1萬 USD |
| 折舊和攤銷 | 1197.5萬 USD | 1049萬 USD | 923萬 USD | 565.9萬 USD | 124.2萬 USD |
| 營業利益 | −4038.4萬 USD | −2052.3萬 USD | −2784.5萬 USD | −180.4萬 USD | 915.7萬 USD |
| 淨利 | −6653.9萬 USD | −602萬 USD | −1214.8萬 USD | 257.6萬 USD | 300.1萬 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 45%
- 優於預期5次、低於預期6次、符合預期0次
- 平均EPS意外幅度
- -143.66%
- 11 類似報告
- 最新每股收益結果
- -0.05
- 預估-0.09 · 優於預期46.43%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
分析師目標價
平均目標
US$4.88
上漲空間 1.46%價格歷史記錄不可用
最高:US$5.00平均的:US$4.88最低:US$4.75近期分析師行動
CTKB 訊息
CTKB同業公司
繼續GoAI的研究
在 GoAI 中研究CTKBresearch.disclaimer











